Protagonist to Present Four Rusfertide Abstracts, Phase 3 VERIFY and Phase 2 Long-Term PV Data at EHA2026
PTGX•Protagonist Therapeutics will showcase four rusfertide abstracts at the European Hematology Association Congress June 11–14, including Phase 3 VERIFY efficacy and safety subgroup analyses and Phase 2 REVIVE/THRIVE long-term thromboembolic event data. Presentations will also address low- and high-risk polycythemia vera patients, cytoreductive therapy use, disease progression, and patient-reported symptom and fatigue outcomes.
1. EHA2026 Abstract Presentations
Protagonist Therapeutics will present four rusfertide abstracts during Poster Session 1 on June 12, showcasing data from the randomized, controlled Phase 3 VERIFY study and long-term findings from the Phase 2 REVIVE and THRIVE open-label extension trials. The VERIFY analyses evaluate efficacy and safety outcomes across low-risk and high-risk polycythemia vera subgroups, while the REVIVE/THRIVE data detail thromboembolic and disease progression events over extended follow-up.
2. Clinical and Patient-Reported Outcomes
Additional presentations will explore rusfertide’s impact on cytoreductive therapy use in phlebotomy-dependent patients and assess patient-reported symptoms and fatigue measures from the VERIFY study. These insights aim to clarify rusfertide’s potential to reduce reliance on phlebotomy and cytoreductive agents while improving quality-of-life metrics in polycythemia vera.
3. Rusfertide Development and Commercialization
An NDA for rusfertide, a first-in-class hepcidin mimetic peptide co-developed with Takeda Pharmaceuticals, is under priority review with the FDA. Protagonist holds a 50/50 U.S. co-commercialization option and continues to advance multiple peptide candidates, including an approved oral IL-23R antagonist and preclinical obesity and hepcidin mimetic programs.
